Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 6/20 | 0.41 |
| ▸ | ANPEP | P15144 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.34 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.34 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.34 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4368576 | 0.78 | ATM (0.59) | MMP2ANPEPATMFKBP1AKMT2A | |
| SCHEMBL20297852 | 0.78 | — | — | |
| SCHEMBL13409006 | 0.77 | MMP2 (0.44) | MMP2ANPEPATMFKBP1ACACNA1A | |
| SCHEMBL5275231 | 0.72 | MMP2 (0.38) | MMP2ANPEPALDH1A1LMNAMAPT | |
| SCHEMBL4367951 | 0.71 | MMP2 (0.40) | MMP2ANPEPATMFKBP1ACACNA1A | |
| SCHEMBL9130961 | 0.70 | CYP19A1 (0.42) | MMP2ANPEPALDH1A1 | |
| SCHEMBL9738223 | 0.70 | CYP19A1 (0.42) | MMP2ANPEPALDH1A1 | |
| SCHEMBL18007438 | 0.70 | HCAR2 (0.38) | MMP2ANPEPATMFKBP1ACACNA1A | |
| SCHEMBL5062575 | 0.69 | MMP2 (0.42) | MMP2ANPEPALDH1A1 | |
| SCHEMBL701488 | 0.69 | MMP2 (0.42) | MMP2ANPEPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105685-A1 | S-Nitrosothiol Compounds and Related Derivatives | GALLEON PHARMACEUTICALS, INC. | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105685-A1 | S-Nitrosothiol Compounds and Related Derivatives | NNMT, BHMT2, SQOR | MMP2 3986/4885ANPEP 2806/4885ATM 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.